



CONTROVERSES ET ACTUALITÉS EN CHIRURGIE VASCULAIRE
CONTROVERSIES & UPDATES IN VASCULAR SURGERY

JANUARY 25-27 2018



MARRIOTT RIVE GAUCHE & CONFERENCE CENTER, PARIS, FRANCE

An Update On The American Venous Forum Guidelines For Superficial Vein

Peter Gloviczki, MD

Mayo Clinic, Rochester, MN, USA



Disclosure

Speaker name:



Peter Gloviczki.....

- I have the following potential conflicts of interest to report:
- Consulting
- Employment in industry
- Shareholder in a healthcare company
- Owner of a healthcare company
- Other(s)
- I do not have any potential conflict of interest**

Conflict of Interest

None

American Venous Forum Guidelines on Superficial Venous Disease



TOP 10 GUIDELINES

10. We recommend using the CEAP classification to describe chronic venous disorders. (GRADE 1B)

Chronic Venous Disorders



C1



C2



C3



C4



C5



C6

Chronic Venous Disease

Chronic Venous Insufficiency

9. Evaluation with Duplex Ultrasound

A cutoff values for reflux


- femoral and popliteal veins: 1 second
- GVS, SSV, tibial, deep femoral veins: 500ms

(GRADE 1B)

“Pathologic” perforating veins

- Reflux time: ≥ 500 ms
- Diameter: ≥ 3.5 mm
- Location: beneath healed or open venous ulcers

(GRADE 1B)



8. We suggest compression therapy using moderate pressure (20-30 mm Hg) for patients with symptomatic varicose veins. (GRADE 2C)

- 1. Palfreyman SJ, Michaels JA. A systematic review of compression hosiery for uncomplicated varicose veins. *Phlebology*. 2009;24 Suppl 1:13-33.**
- 2. Amsler F, Blattler W. Compression therapy for occupational leg symptoms and chronic venous disorders: a meta-analysis of randomised controlled trials. *Eur J Vasc Endovasc Surg*. 2008 Mar;35(3):366-72.**

7. We recommend against compression therapy as the primary treatment of symptomatic varicose veins in patients who are candidates for saphenous vein ablation. (GRADE 1B)

Randomized clinical trial

Randomized clinical trial comparing surgery with conservative treatment for uncomplicated varicose veins

J. A. Michaels¹, J. E. Brazier², W. B. Campbell³, J. B. MacIntyre³, S. J. Palfreyman¹ and J. Ratcliffe²

¹Sheffield Vascular Institute, Northern General Hospital, and ²Health Economics and Decision Science, University of Sheffield, Sheffield and ³Royal Devon and Exeter Hospital, Exeter, UK

Correspondence to: Prof. J. A. Michaels, Academic Vascular Unit, Colindale Avenue, Northwick Park Hospital, Uxbridge, Middlesex UB8 3PH, UK (e-mail: j.michaels@shef.ac.uk)

Background: Surgical treatment of me effectiveness remains uncertain.

Methods: A randomized clinical trial hospitals in different parts of the UK 536 consecutive referrals to vascular for surgical treatment. Conservative n surgical treatment (flush ligation of sit phlebectomies, as appropriate). Chang 6D and EuroQol (EQ) 5D, quality of l treatment, symptomatic measures, and

Results: In the first 2 years after 0.083 (95 per cent confidence the SF-6D score and 0.12 were also seen in sv

Conclusion: Sv life in patients referred to secondary ca



Paper accepted 29 October 2005

Published online in Wiley InterScience (www.bjs.co

REACTIVE TRIAL

246 patients

At 2 years HLS and phlebectomy provided better symptomatic relief, cosmetic results and significantly more improvement in quality of life than conservative management



The SVS/AVF, the UK NICE and the European Guidelines

Recommend against compression therapy as the primary treatment if the patient is a candidate for saphenous vein ablation


Grade of recommendation: 1 (Strong)

Level of Evidence: B (Moderate Quality)

6. We recommend compression as primary treatment for healing venous ulcers.

(GRADE 1A)

Ulcer Healing at 4 years ESCHAR Trial



Gohel MS et al, BMJ. 335(7610):83, 2007 Jul 14.

5. We recommend endovenous thermal ablations (laser and radiofrequency ablations) and ultrasound guided foam sclerotherapy over surgery for treatment of saphenous incompetence.

(GRADE 1B)



A review of randomised controlled trials comparing ultrasound-guided foam sclerotherapy with endothermal ablation for the treatment of great saphenous varicose veins

Huw OB Davies¹, Matthew Popplewell¹, Katy Darvall², Gareth Bate¹ and Andrew W Bradbury¹

Abstract

Objective: The last 10 years have seen the introduction into everyday clinical practice of a wide range of novel non-surgical treatments for varicose veins. The following review compares the following treatments: endothermal ablation, surgery and ultrasound-guided foam sclerotherapy.

Methods: A search of the literature was conducted to identify randomised controlled trials comparing the above treatments.

Results: The review identified 10 randomised controlled trials comparing the above treatments.

Conclusions: The review identified 10 randomised controlled trials comparing the above treatments.

Keywords: Varicose veins

Introduction: For almost 100 years, the treatment for varicose veins (VV) has been surgery. However, over the last 10 years a wide range of novel non-surgical, local and tumescent anaesthetic, treatment modalities have been described, evaluated and entered clinical practice around the world.

In July 2013, the UK National Institute for Health and Care Excellence (NICE) recommended (Clinical Guideline, CG, 168) the following treatment hierarchy for VV: endothermal ablation (ETA), ultrasound-guided foam sclerotherapy (UGFS), surgery and

- All endovenous treatments are safe, with low complication rate and morbidity
- Interventions resulted in significant and clinically important improvement in symptoms and signs
- All interventions result in significant improvement in QoL!

(VSOBT) and Royal College of Surgeons (RCS) Commissioning Guide published in December 2013²

¹Department of Vascular Surgery, University of Birmingham, Solihull Hospital, Birmingham, UK

²North Devon District Hospital, Barnstaple, Devon, UK

Corresponding author:

Huw Davies, Department of Vascular Surgery, University of Birmingham, Solihull Hospital, Netherwood House, Birmingham B91 2JL, UK.
Email: huw.davies@heartofengland.nhs.uk

A Randomized Trial Comparing Treatments for Varicose Veins

Julie Brittenden, M.D., Seonaidh C. Cotton, Ph.D., Andrew Elders, M.Sc., Craig R. Ramsay, Ph.D., John Norrie, M.Sc., Jennifer Burr, M.D., Bruce Campbell, M.B., B.S., Paul Bachoo, M.B., Ch.B., Ian Chetter, M.B., Ch.B., M.D., Michael Gough, M.B., Ch.B., Jonathan Earnshaw, D.M., Tim Lees, M.B., Ch.B., M.D., Julian Scott, M.B., Ch.B., M.D., Sara A. Baker, M.Sc., Jill Francis, Ph.D., Emma Tassie, M.Sc., Graham Scotland, Ph.D., Samantha Willeman, Ph.D., and Marion K. Campbell, Ph.D.

Randomized clinical trial comparing endovenous laser ablation, radiofrequency ablation, foam sclerotherapy and surgical stripping for great saphenous varicose veins

L. H. Rasmussen, M. Lawaetz, L. Bjoern, B. Vennits, A. Blemings and B. Eklof

Danish Vein Centres, Naesved, and Surgical Centre Roskilde, Roskilde, Denmark
Correspondence to: Dr L. H. Rasmussen, Danish Vein Centres, Eskadronvej 4A, 4700 Naesved, Denmark (e-mail: lhr@varix.dk)

Comparing endovenous laser ablation, foam sclerotherapy, and conventional surgery for great saphenous varicose veins

Anke A. M. Biemans, MD,^a Michael Kockaert, MD,^a George P. Akkersdijk, MD,^{b,c} Renate R. van den Bos, MD, PhD,^a Marianne G. R. de Maesseneer, MD, PhD,^{a,c} Philip Cuypers, MD, PhD,^d Theo Stijnen, PhD,^e Martino H. A. Neumann, MD, PhD,^a and Tamar Nijsten, MD, PhD,^a Rotterdam, Eindhoven, and Leiden, The Netherlands; and Antwerp, Belgium

Contents lists available at SciVerse ScienceDirect

ELSEVIER



European Journal of Vascular and Endovascular Surgery

Journal homepage: www.ejves.com

esvs Journal

Cost and Effectiveness of Laser with Phlebectomies Compared with Foam Sclerotherapy in Superficial Venous Insufficiency. Early Results of a Randomised Controlled Trial¹⁶

C.R. Lattimer^{a,*}, M. Azzam^a, E. Kalodiki^a, E. Shawish^a, P. Trueman^b, G. Geroulakos^a



The AVF, the UK NICE and the European Guidelines

Recommend endovenous thermal ablation (RF or laser) or ultrasound guided foam sclerotherapy (UGFS) over high ligation and stripping

Grade of recommendation: 1 (Strong)

Level of Evidence: B (Moderate Quality)

Systematic review and meta-analysis of endovascular and surgical revascularization for patients with chronic lower extremity venous insufficiency and varicose veins



Sreekanth Vemulapalli, MD,^{a,b} Kishan Parikh, MD,^b Remy Coeytaux, MD, PhD,^{a,c,d} Victor Hasselblad, PhD,^e Amanda McBroom, PhD,^{a,d} Abigail Johnston, BA,^f Giselle Raitz, MD,^g Matthew J. Crowley, MD, MHSc,^g Kathryn R. Lallinger, MSLS,^{a,d} W. Schuyler Jones, MD,^{a,b} and Gillian D. Sanders, PhD^{a,d,h} *Durham, NC*

Background Chronic lower extremity venous disease (LECMD) is twice as prevalent as coronary heart disease, and invasive therapies to treat LECVD accounted for an estimated \$290 million in Medicare expenditures in 2015. Despite increasing use of these invasive therapies, their comparative effectiveness is unknown.

Methods We conducted a systematic review and meta-analysis of treatments for patients (symptomatic and asymptomatic) with lower extremity varicosities and/or lower extremity chronic venous insufficiency/incompetence/reflux. We searched PubMed, Embase, and the Cochrane Database of Systematic Reviews for relevant English-language studies published from January 2000 to July 2016. We included comparative randomized controlled trials (RCTs) with >20 patients and observational studies with >500 patients. Short, intermediate, and long-term outcomes of placebo, mechanical compression therapy, and invasive therapies (surgical and endovascular) were included. Quality ratings and evidence grading was performed. Random-effects models were used to compute summary estimates of effects.

Results We identified a total of 57 studies representing 105,878 enrolled patients, including 53 RCTs comprised of 10,034 patients. Among the RCTs, 16 were good quality, 28 were fair quality, and 9 were poor quality. Allocation concealment, double blinding, and reporting bias were inadequately addressed in 25 of 53 (47%), 46 of 53 (87%), and 15 of 53 (28.3%), respectively. Heterogeneity in therapies, populations, and/or outcomes prohibited meta-analysis of comparisons between different endovascular therapies and between endovascular intervention and placebo/compression. Meta-analysis evaluating venous stripping plus ligation (high ligation/stripping) compared with radiofrequency ablation revealed no difference in short-term bleeding [odds ratio (OR) = 0.30, 95% CI -0.16 to 5.38, $P = .43$] or reflux recurrence at 1-2 years [OR = 0.76, 95% CI 0.37-1.55, $P = .44$]. Meta-analysis evaluating high ligation/stripping versus endovascular laser ablation revealed no difference in long-term symptom score [OR 0.02, 95% CI -0.19 to 0.23, $P = .84$] or quality of life at 2 years [OR 0.06, 95% CI -0.12 to 0.25, $P = .50$].

Conclusions The paucity of high-quality comparative effectiveness and safety data in LECVD is concerning given the overall rise in endovascular procedures. More high-quality studies are needed to determine comparative effectiveness and guide policy and practice. [Am Heart J 2018;196:131-143.]

Systematic review and meta-analysis of randomized controlled trials evaluating long-term outcomes of endovenous management of lower extremity varicose veins

Elrasheid A. H. Kheirleiseid, PhD, FRCS, Gillian Crowe, MBBS, Rishabh Sehgal, MD, MRCS, Dimitrios Liakopoulos, MD, Hafiz Bela, MD, Edward Mulkern, MD, FRCS, Ciaran McDonnell, MD, FRCS, and Martin O'Donohoe, MCh, FRCS, *Dublin, Ireland*

ABSTRACT

Background: Early studies have demonstrated that endovenous therapy for varicose veins is associated with a faster recovery and lower complication rates compared with conventional therapy. More than one million procedures have been performed worldwide. The objective of this study was to determine long-term efficacy of currently available endovenous therapy methods for varicose veins compared with conventional surgery (saphenofemoral ligation and stripping of great saphenous vein [GSV] with or without multiple avulsions) in management of GSV-related varicose veins.

Methods: In July 2017, we searched MEDLINE, Cumulative Index to Nursing and Allied Health Literature, Embase, Scopus, Cochrane Library, and Web of Science without date or language restriction for relevant randomized controlled trials (RCTs). Bibliographies of included studies were also searched for additional studies. RCTs comparing conventional surgery and endovenous therapy for treating lower extremity varicose veins with 5 years or more of follow-up were selected. Data extraction and quality assessment were performed independently by two review authors, and any disagreements were resolved by consensus or by arbitration of a third author. Cochrane RevMan 5 was used for analysis.

Results: At time of data extraction, long-term follow-up was available for endovenous laser therapy (EVLT), radiofrequency ablation (RFA), and ultrasound-guided foam sclerotherapy. Included in the review were nine RCTs. The RCTs included 2185 legs; however, only 1352 legs were followed up for 5 years (61.9%). There was no statically significant difference in recurrence rate in comparing EVLT with conventional surgery in treating GSV incompetence (36.6% vs 33.3%, respectively; pooled risk ratio, 1.35 [95% confidence interval, 0.76-2.37]; $P = .3$). Also, no significant difference was determined for recurrence rate in comparing RFA with surgery or EVLT.

Conclusions: Although the analysis showed that EVLT and RFA are as effective as conventional surgery in treating saphenous venous insufficiency, the number of patients available for analysis was too small for definitive conclusions to be drawn. (J Vasc Surg: Venous and Lym Dis 2017;■1-15.)

4. We recommend mini-phlebectomy under local anesthesia for treatment of varicose tributaries, either simultaneously with saphenous ablation or at a later stage.

(GRADE 1B)

3. For perforator vein ablation, we suggest percutaneous techniques over the SEPS procedure

(GRADE 2C)

2. We recommend against selective treatment of perforating vein in patients with simple varicose veins


(C2). GRADE 1B

1. Kianifard B, et al. Randomized clinical trial of the effect of adding subfascial endoscopic perforator surgery to standard great saphenous vein stripping. Br J Surg. 2007 Sep;94(9):1075-80.
2. van Gent WB et al Conservative versus surgical treatment of venous leg ulcers: a prospective, randomized, multicenter trial. J Vasc Surg. 2006 Sep;44(3):563-71.

1. For prevention of venous ulcer recurrence we recommend ablation of the incompetent superficial veins over compression therapy alone.

(GRADE 1B)

Ulcer Recurrence at 4 years ESCHAR Trial



	Numbers at risk				
	0	1	2	3	4
Compression plus surgery	216	166	124	68	27
Compression alone	226	139	98	45	10

Gohel MS et al, BMJ. 335(7610):83, 2007 Jul 14.

Emerging Non-thermal Non-tumescent Endovenous Technologies suggested for Saphenous Ablation

- **Mechanical Occlusion Chemically Assisted (MOCA)**

GRADE 2 B

- **Cyanoacrylate Embolization (CAE).**

GRADE 2 C

A systematic review and meta-analysis of two novel techniques of nonthermal endovenous ablation of the great saphenous vein



Cornelis G. Vos, MD, PhD,^a Çağdaş Ünlü, MD, PhD,^a Jan Bosma, MD, PhD,^b Clarissa J. van Vlijmen, MD, PhD,^c A. Joranne de Nie, MD,^a and Michiel A. Schreve, MD,^a Alkmaar and Amsterdam, The Netherlands


ABSTRACT

Background: Endothermal treatment of the great saphenous vein (GSV) has become the first-line treatment for superficial venous reflux. Nonthermal ablation has potential benefits for acceptability by patients and decreased risk of nerve injury. We performed a systematic review and meta-analysis to evaluate the efficacy of mechanochemical endovenous ablation (MOCA) and cyanoacrylate vein ablation (CAVA) for GSV incompetence.

Methods: MEDLINE, Embase, Cumulative Index to Nursing and Biomedicine, and Cochrane were searched for papers published between January 1990 and January 2017. Studies included patients treated for GSV incompetence with MOCA or CAVA. Data were extracted on patient characteristics, available, case reports, retrospective studies, and randomized controlled trials. Primary outcomes were initial technical success, venous reflux, and recurrence. Secondary outcomes were initial technical success, venous reflux, and recurrence. Venous reflux was measured by duplex ultrasound. Recurrence was measured by duplex ultrasound. Complications were recorded.

Results: Fifteen studies (2 RCTs) involving 1645 patients were included. The mean age was 56 years. The mean follow-up was 12 months. The mean initial technical success was 94.7% for MOCA and 94.8% for CAVA at 6 months. The mean recurrence rate was 5.3% for MOCA and 5.2% for CAVA at 6 months. The mean VCSS score was 1.5 at baseline and 1.2 at 6 months. The mean Aberdeen VVQ score was 1.5 at baseline and 1.2 at 6 months. Questionnaire scores were significantly improved after both treatments.

Conclusions: These results suggest that MOCA and CAVA are effective and safe techniques for GSV incompetence. However, to determine the long-term efficacy and safety, larger randomized controlled trials comparing these novel modalities with endothermal ablation are needed. (DOI: 10.1097/JVS.0000000000000175)



15 studies (2 RCTs), 1645 patients

- **Anatomic success for MOCA (n=691) and CAVA (n=954) was**
 - **94.7% and 94.8% at 6 months**
 - **94.1% and 89.0% at 1 year**
- **VCSS and Aberdeen VVQ score significantly improved after both treatment**

TAKE HOME MESSAGE

- Evidence based guidelines should be consulted for correct evaluation and treatment of venous disease
- Some of the technology is either not available for the physician or not affordable for the patient

Thank You!

